An MPO inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

4-Aminobenzoic Acid hydrazide

Item No. 14845

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-amino-benzoic acid, hydrazide
CAS Number
5351-17-7
Synonyms
  • 4-ABAH
  • Myeloperoxidase Inhibitor 1
  • NSC 640
Molecular Formula
C7H9N3O
Formula Weight
151.2
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 14 mg/mlDMSO:PBS(pH7.2) (1:1): 0.5 mg/ml
λmax
282 nm
SMILES
NC1=CC=C(C(NN)=O)C=C1
InChi Code
InChI=1S/C7H9N3O/c8-6-3-1-5(2-4-6)7(11)10-9/h1-4H,8-9H2,(H,10,11)
InChi Key
WPBZMCGPFHZRHJ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 mg

    $42

    Add

    1 g

    $71

    Add
    NET Formation Screening & Analysis Services
    Our experts are here to help.
    • Detection of NET formation ex vivo and screening for modulators using:
      • High-content imaging
      • Enzymatic detection
      • Citrullination/carbamylation detection
    • Experienced scientists skilled in neutrophil biology, isolation, and handling
    LEARN MORE
    Product Description

    4-Aminobenzoic acid hydrazide (4-ABAH) is an irreversible inhibitor of myeloperoxidase (MPO; IC50 = 0.3 µM).1 It reduces the production of hypochlorous acid (HOCl) induced by opsonized zymosan or phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) in isolated human neutrophils with IC50 values of 16 and 2.2 µM, respectively. 4-ABAH inhibits PMA-induced formation of neutrophil extracellular traps (NETs) in the same cells.2 It reduces infarct volume and the severity of neurological deficits, as well as increases survival, in a mouse model of cerebral ischemia induced by transient middle cerebral artery occlusion (MCAO) when administered at a dose of 40 mg/kg twice per day.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kettle, A.J., Gedye, C.A., Hampton, M.B., et al. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem. J. 308, 559-563 (1995).

    2. Nakabo, S., Ohmura, K., Akizuki, S., et al. Activated neutrophil carbamylates albumin via the release of myeloperoxidase and reactive oxygen species regardless of NETosis. Mod. Rheumatol. 30(2), 345-349 (2019).

    3. Forghani, R., Kim, H.J., Wojtkiewicz, G.R., et al. Myeloperoxidase propagates damage and is a potential therapeutic target for subacute stroke. J. Cereb. Blood Flow Metab. 35(3), 485-493 (2015).

    Product Citations

    Kim, R., Hashimoto, A., Markosyan, N., et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature 612(7939), 338-346 (2022).

    Nakabo, S., Ohmura, K., Akizuki, S., et al. Activated neutrophil carbamylates albumin via the release of myeloperoxidase and reactive oxygen species regardless of NETosis. Mod. Rheumatol. 30(2), 345-349 (2019).